“…In light of the fact that breathing dysfunction in RTT patients improves with relaxation or sleep (Weese-Mayer et al, 2008; Katz et al, 2009; Ren et al, 2012; Ramirez et al, 2013), we considered the possibility that, rather than, or in addition to, any direct effects on respiratory control per se, LM22A-4 might also improve breathing by inducing sedation. Indeed, other studies have shown that apneic breathing in RTT mouse models is reduced by drugs with sedating or anxiolytic effects, including the GABA uptake inhibitor NO-711 (Abdala et al, 2010), the GABA A partial agonist L838,417 (Abdala et al, 2010), the 5-HT1A antagonist 8-OH-DPAT (Abdala et al, 2010), the benzodiazepines midazolam (Voituron and Hilaire, 2011) and diazepam (Abdala et al, 2010), the norepinephrine uptake inhibitor desipramine (Roux et al, 2007; Zanella et al, 2008), and the corticotropin-releasing hormone receptor 1 antagonist antalarmin (Ren et al, 2012).…”